Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Targeting Tyrosine Kinases in Cancer: The Second Wave
Jose Baselga
One of the most exciting developments in cancer research inrecent years has been the clinical validation of molecularlytargeted drugs that inhibit the action of pathogenic tyrosinekinases. Treatment of appropriately selected patients with thesedrugs can alter the natural history of their disease and improvesurvival. The clinical validation of these "first-generation"tyrosine kinase inhibitors has been the prelude to a secondwave of advances in molecular targeting that is expected tofurther change the way we classify and treat cancer. Effortsare now being directed at identifying the tumor subtypes andpatients who will benefit the most from these drugs. In addition,new compounds that circumvent acquired resistance to the first-generationtyrosine kinase inhibitors are being tested in patients withrefractory disease. Agents directed against new molecular targetsare also being explored.
Oncology Program, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Universidad Autónoma de Barcelona, Barcelona 08035, Spain.
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy.
H. Jarvelainen, A. Sainio, M. Koulu, T. N. Wight, and R. Penttinen (2009)
Pharmacol. Rev.
61, 198-223
|Abstract »|Full Text »|PDF »
The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis: A Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral Tongue.
D. Sano, S. Choi, Z. L. Milas, G. Zhou, C. E. Galer, Y.-W. Su, M. Gule, M. Zhao, Z. Zhu, and J. N. Myers (2009)
Arch Otolaryngol Head Neck Surg
135, 411-420
|Abstract »|Full Text »|PDF »
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories.
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
F. Carlomagno, T. Guida, S. Anaganti, L. Provitera, S. Kjaer, N. Q McDonald, A. J Ryan, and M. Santoro (2009)
Endocr. Relat. Cancer
16, 233-241
|Abstract »|Full Text »|PDF »
High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications.
A. Card, C. Caldwell, H. Min, B. Lokchander, Hualin Xi, S. Sciabola, A. V. Kamath, S. L. Clugston, W. R. Tschantz, Leyu Wang, et al. (2009)
J Biomol Screen
14, 31-42
|Abstract »|PDF »
Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
P. Ross-Macdonald, H. de Silva, Q. Guo, H. Xiao, C.-Y. Hung, B. Penhallow, J. Markwalder, L. He, R. M. Attar, T.-a. Lin, et al. (2008)
Mol. Cancer Ther.
7, 3490-3498
|Abstract »|Full Text »|PDF »
Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors.
M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke (2008)
J. Clin. Endocrinol. Metab.
93, 3286-3294
|Abstract »|Full Text »|PDF »
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies.
M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W.H.I. Parren, J. G.J. van de Winkel, et al. (2008)
Cancer Res.
68, 4998-5003
|Abstract »|Full Text »|PDF »
Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases.
A. Pierce, R. D. Unwin, C. A. Evans, S. Griffiths, L. Carney, L. Zhang, E. Jaworska, C.-F. Lee, D. Blinco, M. J. Okoniewski, et al. (2008)
Mol. Cell. Proteomics
7, 853-863
|Abstract »|Full Text »|PDF »
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors.
P. Accornero, G. Lattanzio, T. Mangano, R. Chiarle, R. Taulli, F. Bersani, P. E. Forni, S. Miretti, C. Scuoppo, W. Dastru, et al. (2008)
Clin. Cancer Res.
14, 2220-2226
|Abstract »|Full Text »|PDF »
Prediction of Cancer Driver Mutations in Protein Kinases.
From the Cover: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
J. Tsai, J. T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N. K. Haass, et al. (2008)
PNAS
105, 3041-3046
|Abstract »|Full Text »|PDF »
Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe.
P. Diagaradjane, J. M. Orenstein-Cardona, N. E. Colon-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D. L. Schwartz, J. G. Gelovani, and S. Krishnan (2008)
Clin. Cancer Res.
14, 731-741
|Abstract »|Full Text »|PDF »
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib.
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al. (2008)
Cancer Res.
68, 571-579
|Abstract »|Full Text »|PDF »
Reinduction of ErbB2 in astrocytes promotes radial glial progenitor identity in adult cerebral cortex.
H.T. Ghashghaei, J. M. Weimer, R. S. Schmid, Y. Yokota, K. D. McCarthy, B. Popko, and E.S. Anton (2007)
Genes & Dev.
21, 3258-3271
|Abstract »|Full Text »|PDF »
Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244.
D. W. Ball, N. Jin, D. M. Rosen, A. Dackiw, D. Sidransky, M. Xing, and B. D. Nelkin (2007)
J. Clin. Endocrinol. Metab.
92, 4712-4718
|Abstract »|Full Text »|PDF »
In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor {beta} Using a Generalized Proximity Ligation Method.
M. Jarvius, J. Paulsson, I. Weibrecht, K.-J. Leuchowius, A.-C. Andersson, C. Wahlby, M. Gullberg, J. Botling, T. Sjoblom, B. Markova, et al. (2007)
Mol. Cell. Proteomics
6, 1500-1509
|Abstract »|Full Text »|PDF »
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
S. C. Kiley and R. L. Chevalier (2007)
Am J Physiol Renal Physiol
293, F895-F903
|Abstract »|Full Text »|PDF »
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
C. Peng, J. Brain, Y. Hu, A. Goodrich, L. Kong, D. Grayzel, R. Pak, M. Read, and S. Li (2007)
Blood
110, 678-685
|Abstract »|Full Text »|PDF »
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas.
s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis.
J. Li, R. Berbeco, R. J. Distel, P. A. Janne, L. Wang, and G. M. Makrigiorgos (2007)
Nucleic Acids Res.
35, e84
|Abstract »|Full Text »|PDF »
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms.
H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P.-P. Kung, et al. (2007)
Cancer Res.
67, 4408-4417
|Abstract »|Full Text »|PDF »
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer.
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al. (2007)
J Natl Cancer Inst
99, 628-638
|Abstract »|Full Text »|PDF »
A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts.
N. Puri, A. Khramtsov, S. Ahmed, V. Nallasura, J. T. Hetzel, R. Jagadeeswaran, G. Karczmar, and R. Salgia (2007)
Cancer Res.
67, 3529-3534
|Abstract »|Full Text »|PDF »
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor.
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin (2007)
Clin. Cancer Res.
13, 1540-1551
|Abstract »|Full Text »|PDF »
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors.
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel (2007)
Clin. Cancer Res.
13, 378-381
|Abstract »|Full Text »|PDF »
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b.
G. K. Scott, A. Goga, D. Bhaumik, C. E. Berger, C. S. Sullivan, and C. C. Benz (2007)
J. Biol. Chem.
282, 1479-1486
|Abstract »|Full Text »|PDF »
Stimulatory autoantibodies to the PDGF receptor in scleroderma..
H. Okamoto, E. Lozano, M. Segarra, M. C. Cid, A. Gabrielli, S. S. Baroni, E. V. Avvedimento, and F. K. Tan (2006)
N. Engl. J. Med.
355, 1278
|Full Text »|PDF »
